在含有多替拉韦的初始治疗中出现整合酶耐药突变。
Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
机构信息
Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles (UCLA).
VA Greater Los Angeles Healthcare System.
出版信息
Clin Infect Dis. 2018 Aug 16;67(5):791-794. doi: 10.1093/cid/ciy228.
Abstract
Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.
摘要
多替拉韦（DTG）是治疗人类免疫缺陷病毒 1 型感染的首选药物。我们报告了一名初治患者在替诺福韦二吡呋酯/恩曲他滨加 DTG 治疗期间病毒学失败时的整合酶基因分型的下一代测序分析。
相似文献
1
Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.在含有多替拉韦的初始治疗中出现整合酶耐药突变。
Clin Infect Dis. 2018 Aug 16;67(5):791-794. doi: 10.1093/cid/ciy228.
2
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.在改用多替拉韦单药治疗后，HIV-1整合酶中出现G118R突变，导致对整合酶抑制剂产生交叉耐药。
J Antimicrob Chemother. 2016 Jul;71(7):1948-53. doi: 10.1093/jac/dkw071. Epub 2016 Mar 29.
3
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.阿巴卡韦/多替拉韦/拉米夫定单片复方制剂：在人类免疫缺陷病毒 1 型感染中的应用评价。
Drugs. 2015 Apr;75(5):503-14. doi: 10.1007/s40265-015-0361-6.
4
5
Is resistance to dolutegravir possible when this drug is used in first-line therapy?当多替拉韦用于一线治疗时，是否有可能出现对它的耐药性？
Viruses. 2014 Aug 27;6(9):3377-85. doi: 10.3390/v6093377.
6
Low-cost urine tenofovir assay to triage dolutegravir resistance testing.用于分诊多替拉韦耐药性检测的低成本尿液替诺福韦检测法。
Lancet HIV. 2024 May;11(5):e282-e283. doi: 10.1016/S2352-3018(24)00060-2. Epub 2024 Mar 7.
7
Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.在撒哈拉以南非洲地区将基于多替拉韦的方案扩大规模所面临的挑战。
AIDS. 2020 Apr 1;34(5):783-787. doi: 10.1097/QAD.0000000000002470.
8
Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.HIV-1 3'-多聚嘌呤序列中的突变可导致对多替拉韦产生耐药性。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0102721. doi: 10.1128/AAC.01027-21. Epub 2021 Oct 11.
9
Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir.寡核苷酸连接分析（OLA）探针用于检测 HIV-1 对多替拉韦耐药的开发和优化。
Viruses. 2024 Jul 19;16(7):1162. doi: 10.3390/v16071162.
10
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.喀麦隆重组亚型 CRF02_AG 中鉴定的统计学富集突变的相互作用分析，这些突变可能影响多替拉韦耐药突变的产生。
BMC Infect Dis. 2021 Apr 23;21(1):379. doi: 10.1186/s12879-021-06059-x.
引用本文的文献
1
Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025.2025年美国疾病控制与预防中心关于性接触、注射吸毒或其他非职业性接触HIV后抗逆转录病毒暴露后预防的建议
MMWR Recomm Rep. 2025 May 8;74(1):1-56. doi: 10.15585/mmwr.rr7401a1.
2
Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir.寡核苷酸连接分析（OLA）探针用于检测 HIV-1 对多替拉韦耐药的开发和优化。
Viruses. 2024 Jul 19;16(7):1162. doi: 10.3390/v16071162.
3
Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.初治人类免疫缺陷病毒 1 型整合酶抑制剂人群中出现的治疗中出现的多替拉韦耐药突变：快速范围界定综述。
Viruses. 2023 Sep 15;15(9):1932. doi: 10.3390/v15091932.
4
Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants.HIV-1 整合酶对多替拉韦的耐药机制及对耐药变异体的强效抑制作用。
Sci Adv. 2023 Jul 21;9(29):eadg5953. doi: 10.1126/sciadv.adg5953.
5
A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants.整合酶抑制剂（INSTIs）抗新兴和不断进化的耐药性 HIV-1 整合酶突变体的计算概述。
Arch Microbiol. 2023 Mar 26;205(4):142. doi: 10.1007/s00203-023-03461-8.
6
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.在多替拉韦利匹韦林二线抗反转录病毒治疗中回收替诺福韦：72 周的结局和病毒载量轨迹。
J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):422-429. doi: 10.1097/QAI.0000000000003157.
7
Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.即时检测 HIV-1 感染者治疗初期尿液替诺福韦预测治疗失败和耐药性
Clin Infect Dis. 2023 Feb 8;76(3):e553-e560. doi: 10.1093/cid/ciac755.
8
Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.埃塞俄比亚 HIV-1 型 C 亚型感染患者的治疗前整合酶抑制剂耐药性和自然多态性。
Viruses. 2022 Mar 30;14(4):729. doi: 10.3390/v14040729.
9
Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence .在模拟可变依从性的药物浓度下，对 INSTI 包含的方案进行原谅。
Antimicrob Agents Chemother. 2022 May 17;66(5):e0203821. doi: 10.1128/aac.02038-21. Epub 2022 Apr 7.
10
SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression.严重HIV免疫抑制的持续性新冠肺炎患者中SARS-CoV-2的进化及刺突特异性CD4+ T细胞反应
Microorganisms. 2022 Jan 11;10(1):143. doi: 10.3390/microorganisms10010143.
本文引用的文献
1
The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.HIV-1耐药性少数变异体在治疗失败中的作用。
J Infect Dis. 2017 Dec 1;216(suppl_9):S847-S850. doi: 10.1093/infdis/jix430.
2
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.1型人类免疫缺陷病毒耐药突变更新
J Infect Dis. 2017 Dec 1;216(suppl_9):S843-S846. doi: 10.1093/infdis/jix398.
3
Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?我们是否应该在新诊断出人类免疫缺陷病毒的患者中检测基线整合酶耐药？
Clin Infect Dis. 2017 Oct 15;65(8):1274-1281. doi: 10.1093/cid/cix542.
4
Emergent drug resistance with integrase strand transfer inhibitor-based regimens.基于整合酶链转移抑制剂方案的紧急耐药性。
AIDS. 2017 Jun 19;31(10):1425-1434. doi: 10.1097/QAD.0000000000001494.
5
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.初治及曾接受拉替拉韦治疗的、感染多种HIV-1进化枝的患者中整合酶抑制剂（INI）的基因型耐药情况。
J Antimicrob Chemother. 2015 Nov;70(11):3080-6. doi: 10.1093/jac/dkv243. Epub 2015 Aug 26.
6
Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.在接受埃替拉韦韦/考比司他/恩曲他滨/替诺福韦酯富马酸盐治疗的患者中，首次治疗失败时间点的早期耐药性发展分析。
J Antimicrob Chemother. 2015 Sep;70(9):2632-8. doi: 10.1093/jac/dkv149. Epub 2015 Jun 24.
7
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.在初治 HIV-1 感染的成人中，每日一次多替拉韦与达芦那韦/利托那韦比较（FLAMINGO）：随机、开放标签、3b 期研究的 48 周结果。
Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1.
8
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.多替拉韦钠联合阿巴卡韦-拉米夫定治疗人类免疫缺陷病毒 1 型感染。
N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541.
9
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.在初治 HIV-1 感染的成人中，每日一次多替拉韦与每日两次拉替拉韦的疗效比较（SPRING-2 研究）：一项随机、双盲、非劣效性试验的 96 周结果。
Lancet Infect Dis. 2013 Nov;13(11):927-35. doi: 10.1016/S1473-3099(13)70257-3. Epub 2013 Sep 25.
10
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.多替拉韦对比雷特格韦在有 HIV 的抗逆转录病毒治疗经验、整合酶抑制剂初治成人中的疗效：来自随机、双盲、非劣效性 SAILING 研究的第 48 周结果。
Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3.
Zotero 插件